Melasma feels like a moving target. You commit to a "brightening" routine, use it religiously for three months, and the patches sit there — a little lighter one week, back to baseline after a beach weekend, occasionally darker in a mirror you did not expect. Then a dermatologist mentions tranexamic acid, and if you go looking, you find it in two very different places: as a small oral pill that started life as a drug to stop heavy periods and post-surgical bleeding, and as a "2% tranexamic acid" line on the back of a serum.
Both of those forms are real. The evidence for them is not equally strong, and the story of what tranexamic acid can and cannot do for your skin turns out to be more interesting than the label suggests.
What is tranexamic acid, actually?
Tranexamic acid (TXA) is a synthetic lysine analogue. In the body, it blocks the conversion of plasminogen to plasmin — which is why it was originally used, and still is, to reduce bleeding after surgery, dental work and childbirth, and to lighten heavy periods.
That same plasmin-blocking action is what interests dermatologists. UV light triggers plasmin activity in the skin, which in turn tells melanocytes (the pigment-making cells) to switch on tyrosinase and start pumping out more melanin. TXA gets in the way of that whole cascade. In the skin it also appears to dampen the α-MSH signal and reduce prostaglandin E2 release from keratinocytes, both of which normally push melanocytes into overdrive after inflammation or sun exposure (AlJabr, J Cosmetic Dermatology, 2026).
Translated: it is not bleaching pigment out of your skin. It is turning down the signal that tells your skin to make more pigment when it feels attacked — by UV, by acne, by a laser session, by anything inflammatory. That matters, because most stubborn dark marks are not really a pigment-storage problem; they are a pigment-production problem.
Does oral tranexamic acid actually work for melasma?
This is the strongest part of the evidence base. Across randomised trials and reviews, low-dose oral TXA — typically 250 mg twice a day, sometimes up to 500 mg twice daily — has consistently reduced Melasma Area and Severity Index (MASI) scores over roughly eight to twelve weeks (AlJabr, 2026). Improvement usually shows up between weeks four and eight, not immediately.
It has also been studied as a preventive in people who scar or pigment easily after cosmetic procedures. One trial in 82 high-risk patients used 650 mg per day and found it helped both treat and prevent post-inflammatory hyperpigmentation, with a "favourable safety profile" over follow-up periods ranging from two weeks to several years (Chalermchai et al., reviewed in Zhang, 2024).
The dose used in dermatology is a fraction of the dose used to stop surgical bleeding, and side effects at that level are generally mild — GI upset, headaches, occasional menstrual changes. But TXA is antifibrinolytic, meaning it makes clots slightly harder to break down. So it is not a casual "wellness" pill. People with a personal or strong family history of clots, DVT, pulmonary embolism, stroke, or who are on hormonal contraception with clot risk factors, on certain blood thinners, or pregnant, should not take it without a doctor signing off. In Singapore, oral TXA is prescription-only for a reason. If a friend offers you their pills, that is not the win it sounds like.
Does the serum version actually do anything?
This is where it gets interesting — and where marketing runs a little ahead of evidence.
The good news: topical TXA at 2–5% has been compared head-to-head with hydroquinone (the long-standing "gold standard" for melasma) in several trials. A 12-week comparison of 5% topical TXA solution against 3% hydroquinone cream found no meaningful difference in MASI reduction between the two, but the TXA group reported fewer irritant reactions and better satisfaction (AlJabr, 2026). A separate 12-week study in 55 women using a 3% TXA serum showed a significant drop in melanin index versus baseline (Zhang, 2024).
The catch: topical protocols in these trials are wildly inconsistent. Different vehicles, different concentrations, different frequencies, different adjuncts (some pair TXA with kojic acid, niacinamide, or iontophoresis). Some of the most striking topical results come from combination products, which makes it hard to say what the TXA alone is doing. Reviewers repeatedly flag that this variability limits how strongly you can compare studies to each other.
There is also a plain physics problem: TXA is a small hydrophilic molecule and skin is designed to keep water-soluble things out. How much of the 2% on the label actually gets through the stratum corneum and reaches the melanocyte-keratinocyte interface where it needs to act is not the same question as how much is in the bottle. This is one of the honest reasons dermatologists tend to reach for the oral form when a case is stubborn, and reserve the serum for milder pigmentation, maintenance, or people who cannot take the pill.
How does it compare to what is already on your shelf?
If you have been treating dark marks for a while, you probably have niacinamide, vitamin C, azelaic acid or a retinoid somewhere in your routine. It is worth understanding what TXA adds, because the ingredients do not do the same thing.
| Ingredient | What it mostly does | Where TXA differs |
|---|---|---|
| Niacinamide | Blocks pigment transfer from melanocyte to keratinocyte | TXA works one step earlier — on the signal that tells melanocytes to make pigment at all |
| Vitamin C | Antioxidant + tyrosinase inhibitor | Complementary; TXA targets the upstream plasmin/α-MSH pathway rather than the enzyme directly |
| Azelaic acid | Tyrosinase inhibitor + anti-inflammatory | Overlapping anti-inflammatory action; TXA is often stacked with it, not swapped for it |
| Hydroquinone | Directly suppresses melanin synthesis | Comparable efficacy in head-to-head trials; TXA usually better tolerated |
In other words, TXA is not a "better vitamin C". It is playing on a different lever — the inflammation-to-pigment cascade — which is why dermatologists often layer it in rather than pull other things out.
What actually moves melasma (with or without TXA)
Every credible melasma guideline in the last decade lands on the same, slightly annoying answer: the ingredient matters, but daily broad-spectrum sunscreen — reapplied — matters more. The trials showing 40-plus percent MASI reductions on TXA were done alongside strict photoprotection, not instead of it. Skip the SPF and even oral TXA underperforms.
The other unglamorous factor is time. TXA studies run for 8 to 12 weeks because that is roughly how long melasma takes to visibly respond to anything. If you started a serum three weeks ago and the patches are still there, you have not failed the ingredient. You are looking at a snapshot before the story is finished.
Bottom line for a real routine
If your pigmentation is mild-to-moderate, a well-formulated topical TXA — ideally combined with niacinamide, vitamin C or azelaic acid — is a reasonable, low-irritation add. Give it three months alongside daily SPF before you judge it. If it is stubborn, hormonal, or recurrent, that is a conversation for a dermatologist, because oral TXA at the doses shown to work is genuinely a prescription decision, not a self-experiment.
And if you are still deciding whether it is worth starting anything at all: fix the sunscreen first. It is the single change that makes every other pigmentation product in your routine, TXA included, do more of what it claims.
Tranexamic acid is a genuine addition to the pigmentation toolkit, not a replacement for it — and it will always outperform its own marketing when it is paired with the boring habit no serum can substitute for: daily, reapplied sunscreen.
